Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

Azure Power Wins Indian Railway’s Largest Rooftop Auction; Rooftop Portfolio Surpasses 100 MWs

NEW DELHI–(BUSINESS WIRE)–Azure Power (NYSE:AZRE), a leading solar power producer in India, announced that it has won 46 MWs of solar rooftop projects across eleven states pan India for Indian Railways. Indian Railways is the largest rail network in Asia and is owned and operated by the Government of India through the Ministry of Railways.

The power purchase agreement (PPA) will be signed with Indian Railways for their respective zones and coach factory for 25 years. The average tariff for the project is INR 4.63 (~USD 7 cents) per kWh with an additional capital incentive of INR 933.5 million (~US$ 14 million) upon commissioning

Out of the 46 MWs total allocation, 20 MWs has been allocated by Northern Railways division, 10 MWs by the Western Railways division, 10 MWs by the North-Central Railways division, 3 MWs by the North Western Railways division, and 3 MWs by the Rail Coach Factory division.

Inderpreet Wadhwa, Founder and Chief Executive Officer, Azure Power said, “Azure has superior rooftop solar power solutions for infrastructure, commercial and industrial customers in cities across India to lower their energy costs and meet their greenhouse gas (GHG) emission reduction targets. We are pleased to partner with Indian Railways in reducing their GHG emissions through deployment of solar energy at their facilities across locations pan- India.”

With this win, Azure Power rooftop solar portfolio surpassed 100 MWs across 14 states in India. Azure Power recently announced the successful installation and operation of the first phase of its rooftop solar power plant for Delhi Metro Rail Corporation (DMRC). The 14 MW project is one of the largest allocations by DMRC to a solar power company. The project covers DMRC metro stations, workshops and parking lots. Azure Power’s rooftop customers also include large commercial real estate companies, a leading global chain of premium hotels, distribution companies in smart cities, warehouses, DMRC and Delhi water supply company.

About Azure Power

Azure Power (NYSE:AZRE) is a leading solar power producer in India with a total portfolio of over 1,000 MWs across 18 states. It has developed, constructed and operated solar projects of varying sizes, from utility scale to rooftop, since its inception in 2008. Azure Power has a strong track record in delivering solar power projects, from the construction of India’s first private utility scale solar PV power plant in 2009, implementation of the first MW scale rooftop under the smart city initiative in 2013, to the largest solar plant (100 MW) under India’s National Solar Mission (NSM) policy in Jodhpur, Rajasthan. With its in-house engineering, procurement and construction expertise and advanced in-house operations and maintenance capability, Azure Power manages the entire development and operation process, providing low-cost solar power solutions to customers throughout India.

For more information, visit: www.azurepower.com

GEE Group Inc. to Ring NYSE Closing Bell

NAPERVILLE, IL / ACCESSWIRE / March 30, 2017 / GEE Group Inc. (NYSE MKT: JOB) („the Company” or „GEE Group”), a provider of professional staffing services and solutions, today announced that the Company will ring The Closing Bell televised live at the New York Stock Exchange on Monday, April 3rd, 2017 starting at 3:56 pm ET. Members of the GEE Group executive management team and board of directors, investors and invited guests will gather on the podium to ring the NYSE bell during the ceremony.

Chairman and Chief Executive Officer of the Company, Derek Dewan, commented on the bell ringing, stating: „GEE Group is delighted to ring The Closing Bell on behalf of our dedicated employees, associates, customers and investors. We are celebrating our new name, GEE Group, which incorporates our specialty units focused on higher-margin professional staffing services and human resource solutions. GEE Group reached a milestone by almost doubling its fiscal year revenues in one year. Ringing The Closing Bell is a wonderful festivity that has a long history and rich tradition at the New York Stock Exchange. We are pleased to ring The Closing Bell in this historic building, and we are thrilled to take part in this bell ringing ceremony as we continue to grow the Company into an exceptional leader in the staffing industry.” Dewan continued, „We enjoy serving our clients and providing value-added human resource solutions while also providing our workers with premier employment opportunities where they can grow their skills and thrive.”

In addition to live television coverage of the ceremony, the New York Stock Exchange will stream The Closing Bell ringing on its website: https://livestream.com/NYSE. The bell ringing is scheduled for 3:56 – 4:00 p.m. ET. A video of the bell-ringing will also be archived on that same page after the livestream.

About GEE Group Inc.

GEE Group Inc. is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. The Company operates in two industry segments, providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and commercial staffing services through the names of Access Data Consulting, Agile Resources, Ashley Ellis, General Employment, Omni-One, Paladin Consulting, and Triad. Also, in the healthcare sector, GEE Group, through its Scribe Solutions brand, staffs medical scribes who assist physicians in emergency departments of hospitals and in medical practices by providing required documentation for patient care in connection with electronic medical records (EMR).

Forward-Looking Statements

In addition to historical information, this press release contains statements relating to the Company’s future results (including certain projections, pro forma financial information, and business trends) that are „forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, (the „Exchange Act”), and are subject to the „safe harbor” created by those sections. The statements made in this press release that are not historical facts are forward-looking statements that are predictive in nature and depend upon or refer to future events. Such forward-looking statements often contain, or are prefaced by, words such as „will”, „may,” „plans,” „expects,” „anticipates,” „projects,” „predicts,” „estimates,” „aims,” „believes,” „hopes,” „potential,” „intends,” „suggests,” „appears,” „seeks,” or variations of such words or similar words and expressions. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and, consequently, as a result of a number of factors, the Company’s actual results could differ materially from those expressed or implied by such forward-looking statements. Certain factors that might cause the Company’s actual results to differ materially from those in the forward-looking statements include, without limitation: (i) the loss, default or bankruptcy of one or more customers; (ii) changes in general, regional, national or international economic conditions; (iii) an act of war or terrorism or cyber security breach that disrupts business; (iv) changes in the law and regulations; (v) the effect of liabilities and other claims asserted against the Company; (vi) changes in the size and nature of the Company’s competition; (vii) the loss of one or more key executives; (viii) increased credit risk from customers; (ix) the Company’s failure to grow internally or by acquisition or the failure to successfully integrate acquisitions; (x) the Company’s failure to improve operating margins and realize cost efficiencies and economies of scale ; (xi) the Company’s failure to attract, hire and retain quality recruiters, account managers and salesmen; (xii) the Company’s failure to recruit qualified candidates to place at customers for contract or full-time hire; and such other factors as set forth under the heading „Forward-Looking Statements” in the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q and in the Company’s other filings with the Securities and Exchange Commission (SEC). More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company is under no obligation to (and expressly disclaims any such obligation to) and does not intend to publicly update, revise or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Contact:

GEE Group Inc.
Andrew J. Norstrud
813.803.8275
[email protected]

SOURCE: GEE Group Inc.

Research Reports on Banking Equities — Regions Financial, BB&T, First Horizon National, and F.N.B. Corp.

NEW YORK, March 30, 2017 /PRNewswire/ —

The Regional Southeast Banks industry includes small- to mid-sized companies that are located in Southeastern US. On average, these companies tend to pay dividends that are in-line with the wider market. Pre-market, Stock-Callers.com dedicates attention to Regions Financial Corp. (NYSE: RF), BB&T Corp. (NYSE: BBT), First Horizon National Corp. (NYSE: FHN), and F.N.B. Corp. (NYSE: FNB). Learn more about these stocks by accessing their free research reports at:

http://stock-callers.com/registration

Birmingham, Alabama headquartered Regions Financial Corp.’s shares saw a slight decline of 0.62%, finishing Wednesday’s trading session at $14.31. A total volume of 10.77 million shares was traded. The stock has advanced 0.08% since the start of this year. The Company’s shares are trading above their 200-day moving average by 21.55%. Moreover, shares of Regions Financial, which together with its subsidiaries, provides banking and bank-related services to individual and corporate customers in the US, have a Relative Strength Index (RSI) of 40.22.

On March 15th, 2017, research firm FBR & Co. reiterated its ‚Outperform’ rating on the Company’s stock with an increase of the target price from $17 a share to $18 a share.

On March 23rd, 2017, Regions Financial announced that it is scheduled to release its Q1 2017 financial results on Tuesday, April 18th, 2017. Executives from the Company will review Regions Financial’s results via teleconference and live audio webcast beginning at 11 a.m. ET. A news release and additional materials will be available on the Company’s website under Investor Relations prior to the teleconference. Free research report on RF is available at:

http://stock-callers.com/registration/?symbol=RF

BB&T

On Wednesday, shares in Winston-Salem, North Carolina headquartered BB&T Corp. recorded a trading volume of 3.29 million shares, and ended the session 0.96% lower at $44.47. The stock is trading 7.98% above its 200-day moving average. Shares of the Company, which operates as a financial holding company that provides various banking and trust services for small and mid-size businesses, public agencies, local governments, and individuals, have an RSI of 34.88.

On March 15th, 2017, BB&T Corp. announced that it is increasing its prime-lending rate to 4.00% from 3.75% effective immediately. The complimentary research report on BBT can be downloaded at:

http://stock-callers.com/registration/?symbol=BBT

First Horizon National

Shares in Memphis, Tennessee headquartered First Horizon National Corp. closed at $18.32, slightly down 0.33% from the last trading session. The stock recorded a trading volume of 1.84 million shares. The Company’s shares are trading 8.29% above their 200-day moving average. Additionally, shares of First Horizon National, which operates as the bank holding company for First Tennessee Bank National Association that provides various financial services in the US and internationally, have an RSI of 37.50.

On March 14th, 2017, First Horizon National has been honored by the National Association for Female Executives for being one of the 2017 NAFE Top 60 Companies for Executive Women. The annual list is published in Working Mother magazine and recognizes companies across the Country that excels in leadership opportunities for women. Visit us today and access our complete research report on FHN at:

http://stock-callers.com/registration/?symbol=FHN

F.N.B. Corp.

Pittsburgh, Pennsylvania headquartered F.N.B. Corp.’s stock ended 0.68% lower at $14.63 with a total trading volume of 2.87 million shares. The Company’s shares are trading above their 200-day moving average by 7.00%. Shares of the company, which provides a range of financial services to consumers, corporations, governments, and small- to medium-sized businesses primarily in Pennsylvania, eastern Ohio, and northern West Virginia, have an RSI of 40.85.

On March 23rd, 2017, F.N.B. Corp. announced that it expects to issue financial results for Q1 2017 before the market opens on Tuesday, April 25th, 2017. President and CEO, Vincent J. Delie, Jr., CFO, Vincent J. Calabrese, Jr., and Chief Credit Officer, Gary L. Guerrieri, expect to host a conference call to discuss the Company’s financial results the same day at 10:30 AM ET. Get free access to your research report on FNB at:

http://stock-callers.com/registration/?symbol=FNB

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the „Author”) and is fact checked and reviewed by a third party research service company (the „Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com . Rohit Tuli, a CFA® charterholder (the „Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If youre a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

     (Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )

     (Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented „Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added „Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudré-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

SOURCE SYMETIS SA

ReneSola Connects 10MW of Ground-mount Solar Projects to UK Grid

SHANGHAI, March 30, 2017 /PRNewswire/ — ReneSola Ltd (“ReneSola” or the “Company”) (www.renesola.com) (NYSE: SOL), a leading fully-integrated solar project developer and provider of energy-efficient products, today announced the completion and grid connection of two ground-mount projects in the United Kingdom. These projects have a combined capacity of approximately 10 MW. ReneSola managed the design and construction of these projects, and will provide ongoing operation and maintenance services until final acceptance.

These two projects are located in North Yorkshire and Shropshire.  Both projects are qualified under the 1.2 Renewable Obligations Certificate (ROC) program.

Xianshou Li, ReneSola’s Chief Executive Officer, said, “The United Kingdom remains one of our key developed markets for our downstream project business, and we are proud of the continued execution of our downstream strategy in the region. The successful grid connection of these projects solidified our competitive positon in developing downstream projects, and we look forward to driving incremental project development globally.”

About ReneSola

Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE: SOL) is an international leading brand and technology provider of energy efficient products. Leveraging its global presence and expansive distribution and sales network, ReneSola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com.

Safe Harbor Statement

This press release contains statements that constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Whenever you read a statement that is not simply a statement of historical fact (such as when the Company describes what it “believes,” “plans,” “expects” or “anticipates” will occur, what “will” or “could” happen, and other similar statements), you must remember that the Company’s expectations may not be correct, even though it believes that they are reasonable. The Company does not guarantee that the forward-looking statements will happen as described or that they will happen at all. Further information regarding risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements is included in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s annual report on Form 20-F. The Company undertakes no obligation, beyond that required by law, to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made, even though the Company’s situation may change in the future.

For investor and media inquiries, please contact:

In China:

ReneSola Ltd
Ms. Rebecca Shen
+86 (21) 6280-9180 x106
ir@renesola.com

The Blueshirt Group Asia
Mr. Gary Dvorchak, CFA
+86 (138) 1079-1480
gary@blueshirtgroup.com

In the United States:

The Blueshirt Group
Mr. Ralph Fong
+1 (415) 489-2195
ralph@blueshirtgroup.com

SOURCE ReneSola Ltd.

ReneSola Connects 10MW of Ground-mount Solar Projects to UK Grid

SHANGHAI, March 30, 2017 /PRNewswire/ — ReneSola Ltd (“ReneSola” or the “Company”) (www.renesola.com) (NYSE: SOL), a leading fully-integrated solar project developer and provider of energy-efficient products, today announced the completion and grid connection of two ground-mount projects in the United Kingdom. These projects have a combined capacity of approximately 10 MW. ReneSola managed the design and construction of these projects, and will provide ongoing operation and maintenance services until final acceptance.

These two projects are located in North Yorkshire and Shropshire.  Both projects are qualified under the 1.2 Renewable Obligations Certificate (ROC) program.

Xianshou Li, ReneSola’s Chief Executive Officer, said, “The United Kingdom remains one of our key developed markets for our downstream project business, and we are proud of the continued execution of our downstream strategy in the region. The successful grid connection of these projects solidified our competitive positon in developing downstream projects, and we look forward to driving incremental project development globally.”

About ReneSola

Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE: SOL) is an international leading brand and technology provider of energy efficient products. Leveraging its global presence and expansive distribution and sales network, ReneSola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com.

Safe Harbor Statement

This press release contains statements that constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Whenever you read a statement that is not simply a statement of historical fact (such as when the Company describes what it “believes,” “plans,” “expects” or “anticipates” will occur, what “will” or “could” happen, and other similar statements), you must remember that the Company’s expectations may not be correct, even though it believes that they are reasonable. The Company does not guarantee that the forward-looking statements will happen as described or that they will happen at all. Further information regarding risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements is included in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s annual report on Form 20-F. The Company undertakes no obligation, beyond that required by law, to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made, even though the Company’s situation may change in the future.

For investor and media inquiries, please contact:

In China:

ReneSola Ltd
Ms. Rebecca Shen
+86 (21) 6280-9180 x106
ir@renesola.com

The Blueshirt Group Asia
Mr. Gary Dvorchak, CFA
+86 (138) 1079-1480
gary@blueshirtgroup.com

In the United States:

The Blueshirt Group
Mr. Ralph Fong
+1 (415) 489-2195
ralph@blueshirtgroup.com

SOURCE ReneSola Ltd.

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

(Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudre-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com

Symetis and Boston Scientific Reach USD 435 Million Purchase Agreement

ECUBLENS, Switzerland, March 30, 2017 /PRNewswire/ —

  • Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment
  • Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease
  • Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions
  • Symetis’ IPO launched on Euronext Paris and very well received by the investment community, has been halted

Symetis, a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, today announced that it has agreed to be acquired by Boston Scientific for $435 million in an all cash, up-front payment.

(Logo: http://mma.prnewswire.com/media/484319/Symetis_Logo.jpg )
(Photo: http://mma.prnewswire.com/media/484320/Symetis_Acurate_Neo_Valve.jpg )

The acquisition of Symetis by Boston Scientific will allow the company to extend its reach and expand the treatment offerings for patients with aortic valvular heart disease worldwide. The combination of Symetis’ ACURATE valves with the Boston Scientific Lotus™ valve platform, will also enable interventional cardiologists and cardiac surgeons to address varying patient pathologies and anatomies with two complementary and compelling technologies.

Jacques R. Essinger, Ph.D. and CEO, Symetis, commented “Over the past years, Symetis matured into a TAVI (Transcatheter Aortic Valve Implantation) player with fast growth and a solid clinical reputation. The IPO that we were pursuing until yesterday on Euronext Paris was meant to give Symetis the means to commercially expand beyond Europe and to further grow into the exciting field of structural heart. We are very pleased by the positive response we received from the investment community, which we want to thank for the interest it has shown in Symetis. However, as of today, the company is taking another path by joining Boston Scientific. The global scale and strong legacy of Boston Scientific in interventional cardiology will further propel Symetis’ clinical excellence. As a result, we can expect more patients to be better treated for valvular heart disease globally. Moving forward, this means an exciting development path for the Symetis team.”

Dominik Ellenrieder, Symetis’ Chairman, added “Growing at a strong and sustained CAGR of 55% since 2012, Symetis is a success story in the structural heart market. This purchase agreement is a recognition of Symetis’ research and development track record in addressing patients’ needs with innovative structural heart technologies, the company’s manufacturing expertise and its strong relationships with doctors and healthcare professionals. We are excited about the strong potential of our combined strengths to set a new standard in the TAVI market with a broad and clinically differentiated offering.”

Following the purchase agreement reached with Boston Scientific, the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very well received by the investment community and which was originally expected to be completed on 31 March 2017, has been halted. The acquisition of Symetis by Boston Scientific is projected to close during the second quarter of 2017, subject to customary closing conditions.

About Symetis 

Symetis, founded in 2001, is a medical technology company specializing in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions.

Symetis’ products, ACURATE TA™ and ACURATE neo/TF, and their delivery systems are based on proprietary design and delivery technologies and are marketed and sold in key markets in Europe and in other geographies. Symetis’ innovative TAVI solutions are recognized by intervention cardiologists and surgeons for their clinical performance and ease of use.

Growing at a strong and sustained CAGR of 55% since 2012, the company generated revenues of CHF 38.4 million in 2016.

Symetis is a Swiss company with corporate headquarters in Ecublens, Switzerland and its products are produced in Switzerland and Brazil.

For more information visit http://www.symetis.com

Symetis
Khaled Bahi – Chief Financial Officer
+41(0)-21-651-01-60
investors@symetis.com    

Weber Shandwick
Alphonse Daudre-Vignier
+41-(0)-79-127-63-58
adaudre-vignier@webershandwick.com